Search for: All records | NSF Public Access

Note: When clicking on a Digital Object Identifier (DOI) number, you will be taken to an external site maintained by the publisher. Some full text articles may not yet be available without a charge during the embargo (administrative interval).
What is a DOI Number?

Some links on this page may take you to non-federal websites. Their policies may differ from this site.

Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago

https://doi.org/10.1016/j.annepidem.2021.10.006

Mustanski, Brian; Saber, Rana; Ryan, Daniel T.; Benbow, Nanette; Madkins, Krystal; Hayford, Christina; Newcomb, Michael E.; Schrock, Joshua M.; Vaught, Lauren A.; Reiser, Nina L.; et al (February 2022, Annals of Epidemiology)

Full Text Available
Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals.

https://doi.org/10.1016/j.eclinm.2021.101018

Demonbreun, Alexis R.; Sancilio, Amelia; Velez, Matt P.; Ryan, Daniel T.; Saber, Rana; Vaught, Lauren A.; Reiser, Nina L.; Hsieh, Ryan R.; D'Aquila, Richard T.; Mustanski, Brian; et al (August 2021, EClinicalMedicine)

Full Text Available
Cohabitation With a Known Coronavirus Disease 2019 Case Is Associated With Greater Antibody Concentration and Symptom Severity in a Community-Based Sample of Seropositive Adults

https://doi.org/10.1093/ofid/ofab244

Schrock, Joshua M; Ryan, Daniel T; Saber, Rana; Benbow, Nanette; Vaught, Lauren A; Reiser, Nina; Velez, Matthew P; Hsieh, Ryan; Newcomb, Michael; Demonbreun, Alexis R; et al (July 2021, Open Forum Infectious Diseases)

Abstract In a community-based sample of seropositive adults (n = 1101), we found that seropositive individuals who lived with a known coronavirus disease 2019 (COVID-19) case exhibited higher blood anti–severe acute respiratory syndrome coronavirus 2 spike receptor-binding domain immunoglobulin G concentrations and greater symptom severity compared to seropositive individuals who did not live with a known COVID-19 case.
more » « less
Full Text Available
Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure

https://doi.org/10.1172/jci.insight.146148

Demonbreun, Alexis R.; McDade, Thomas W.; Pesce, Lorenzo; Vaught, Lauren A.; Reiser, Nina L.; Bogdanovic, Elena; Velez, Matthew P.; Hsieh, Ryan R.; Simons, Lacy M.; Saber, Rana; et al (May 2021, JCI Insight)

Full Text Available
Low Levels of Neutralizing Antibodies After Natural Infection With Severe Acute Respiratory Syndrome Coronavirus 2 in a Community-Based Serological Study

https://doi.org/10.1093/ofid/ofac055

McDade, Thomas W.; Sancilio, Amelia; D’Aquila, Richard; Mustanski, Brian; Vaught, Lauren A.; Reiser, Nina L.; Velez, Matthew E.; Hsieh, Ryan R.; Ryan, Daniel T.; Saber, Rana; et al (March 2022, Open Forum Infectious Diseases)

Abstract BackgroundConfidence in natural immunity after infection with severe acute respiratory syndrome coronavirus 2 is one reason for vaccine hesitancy. MethodsWe measured antibody-mediated neutralization of spike protein-ACE2 receptor binding in a large community-based sample of seropositive individuals who differed in severity of infection (N = 790). ResultsA total of 39.8% of infections were asymptomatic, 46.5% were symptomatic with no clinical care, 13.8% were symptomatic with clinical care, and 3.7% required hospitalization. Moderate/high neutralizing activity was present after 41.3% of clinically managed infections, in comparison with 7.9% of symptomatic and 1.9% of asymptomatic infections. ConclusionsPrior coronavirus disease 2019 infection does not guarantee a high level of antibody-mediated protection against reinfection in the general population.
more » « less